Carol Bivins

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Alireza Eghtedar, Srđan Verstovšek, Zeev Estrov et al. · Blood · 2012 · 200 citations · Full text

Medicine, Oncology, Pharmacology +15

Troxacitabine, A Novel Dioxolane Nucleoside Analog, Has Activity in Patients With Advanced Leukemia

Francis J. Giles, Jörge E. Cortes, Sharyn D. Baker et al. · Journal of Clinical Oncology · 2001 · 101 citations

Medicine, Oncology, Pharmacology +17

Optimal Frequency of Changing Intravenous Administration Sets: Is It Safe to Prolong Use Beyond 72 Hours?

Issam Raad, Hend Hanna, Abeer Awad et al. · Infection Control and Hospital Epidemiology · 2001 · 97 citations

Pharmacy, Clinical Pharmacy, Oncology +14

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

Prithviraj Bose, David McCue, Sebastian Wurster et al. · Clinical Infectious Diseases · 2020 · 76 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Abhishek Maiti, Courtney D. DiNardo, Wei Qiao et al. · Cancer · 2021 · 51 citations · Full text

Medicine, Oncology, Pharmacology +13